Skip to main content
. 2021 Apr 14;12(4):396. doi: 10.1038/s41419-021-03685-w

Fig. 1. Anlotinib exerts potent cytotoxicity against MM cells.

Fig. 1

A Chemical structure of anlotinib. B MM cell lines (NCI-H929, RPMI-8226, LP1, MM.1S, OPM2, and U266) were treated with anlotinib (0–20 μM) for 48 h, and the cell viability was detected by CCK8. The IC50 value was calculated based on the dose–response curve using Prism 8.0 software. CE NCI-H929, RPMI-8226 and LP1 cells were treated with anlotinib for 24 and 48 h, followed by the assessment of cell viability. F The CD138+ and G CD138 cells isolated from MM patients were treated with anlotinib (0–10 μM) for 24 h, and then the cell viability was assessed. H Normal BMMCs from four healthy donors were treated with anlotinib (0–10 μM) for 24 h. Data are shown as mean ± SD and representative of three independent experiments.